

### AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions and listings of the claims in the application.

1. (currently amended) A method of inhibiting ~~activation~~proliferation of a lymphocyte, the method comprising contacting ~~the an activated~~ lymphocyte with a soluble form of B7-H3 agonist and allowing the soluble form of B7-H3 agonist to inhibit the ~~activation~~proliferation of the lymphocyte.

2. (canceled)

3. (withdrawn) The method as in claim 3, wherein the B7-H3 agonist comprises SEQ ID NO:15.

4. (original) The method as in claim 2, wherein the soluble form comprises at least one V domain of B7-H3.

5. (currently amended) The method as in claim 4, wherein the V domain comprises: (a) SEQ ID NO:7 or (b) an amino acid sequence which is ~~substantially~~at least 90% identical to SEQ ID NO:7 and which competitively inhibits binding of B7-H3 to its receptor.

6. (original) The method as in claim 4, wherein the soluble form of B7-H3 further comprises at least one C domain of B7-H3.

7. (original) The method as in claim 4, wherein the soluble form of B7-H3 further comprises an Fc region of an antibody.

8. (currently amended) The method as in claim 7, wherein the soluble form of B7-H3 comprises: (a) an amino acid sequence chosen from SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22; or (b) an amino acid sequence which is ~~substantially~~at least 90% identical to at least one of the

sequences chosen from SEQ ID NO:16, SEQ ID NO:17, SEQ ID NO:18, SEQ ID NO:19, SEQ ID NO:20, SEQ ID NO:21, or SEQ ID NO:22 and which competitively inhibits binding of B7-H3 to its receptor.

9. (currently amended) The method as in claim 7, wherein the soluble form of B7-H3 comprises: (a) an amino acid sequence chosen from SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14; or (b) an amino acid sequence which is ~~substantially~~ at least 90% identical to at least one of the sequences chosen from SEQ ID NO:10, SEQ ID NO:12, or SEQ ID NO:14 and which competitively inhibits binding of B7-H3 to its receptor.

10. (withdrawn) The method as in claim 3, wherein the B7-H3 agonist is coupled with a primary stimulatory molecule.

11. (withdrawn) The method as in claim 10, wherein the soluble form of B7-H3 and the primary stimulatory molecule are spaced by no more than 100  $\mu\text{m}$ .

12. (withdrawn) The method as in claim 1, wherein the B7-H3 antagonist is a nucleic acid encoding amino acid of SEQ ID NO:15.

13. (withdrawn) A method of enhancing activation of a lymphocyte, the method comprising contacting the lymphocyte with a B7-H3 antagonist and allowing the antagonist to enhance the activation of the lymphocyte.

14. (withdrawn) The method as in claim 13, wherein the lymphocyte is human.

15. (withdrawn) The method as in claim 13, wherein the B7-H3 antagonist is an antibody to B7-H3 or an antibody against a B7-H3 receptor.

16. (withdrawn) The method as in claim 13, wherein the B7-H3 antagonist is an antisense nucleic acid or a siRNA.

17. (currently amended) The method as any one of claims 1[[ or 13]], wherein the lymphocyte is a T cell.

18. (original) The method as in claims 17, wherein the T cell is a CD4<sup>+</sup> T cell.

19. (currently amended) The method as any one of claims[[ 1 or 13]], wherein the lymphocyte is in a mammal.

20. (currently amended) The method as in claim 19, wherein the mammal is afflicted with or is at risk for ~~at least one of: an immunologic disorder, a cancer, or an infectious disease.~~

21. (original) The method as in claim 19, wherein the mammal is treated with Factor VIII or Factor IX.